Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Clinical trial NCT07599007 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07599007
Sponsor: Bristol-Myers Squibb
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Non-Small Cell Lung Cancer

Start date: 2026-05-24
Primary completion: 2027-12-30
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.